

## Special Issue

# Advancing Vaccine Research: Contributions from Molecular, Cellular, and Omics Approaches

### Message from the Guest Editors

Vaccines have long been proven a highly efficient means to confer protection to various infectious diseases, and a rush for protective vaccines against SARS-CoV-2 is ongoing. The fast-developing field of omics sciences is delivering a deluge of nucleotide and protein sequence data from pathogens that, together with powerful bioinformatics tools and databases, are prompting astonishing advances in vaccine development. Advances in cell biology are unravelling nonconventional structures such as membrane vesicles as potential sources and vehicles of antigen presentation and delivery. This Special Issue aims to gather papers that use omics approaches such as genomics and proteomics, alternative biological structures such as extracellular vesicles, or innovative experimental methodologies to identify antigens for subunit vaccine investigation and development, as well as papers on bioinformatics tools, databases, and high-throughput techniques and instrumentation, in order to help in vaccine research and development. Papers in all formats accepted in the journal are welcome.

### Guest Editors

Dr. Jorge H. Leitão

Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal

Prof. Dr. Manuel José Rodríguez-Ortega

Departamento de Bioquímica y Biología Molecular, Universidad de Córdoba Edificio Severo Ochoa Planta Baja, Campus de Rabanales, 14071 Córdoba, Spain

### Deadline for manuscript submissions

closed (15 February 2022)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/64892](https://mdpi.com/si/64892)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).